// App-Quantinova.ai

4707 : Investigating the role of EZH2 as a therapeutic target in clear cell renal cell carcinoma (ccRCC)

Researchers

Presenter

  • Darmood Wei

Principal Investigators

  • Christopher J. Ricketts

  • Laura S. Schmidt

  • Youfeng Yang

  • Cathy D. Vocke

  • William M. Linehan

Medical Centers

  • National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Pancreatic cancer

  • Hodgkin's Lymphoma

  • Gastric Cancer

  • Lung Cancer

  • Solid malignancies

  • Lymphomas

Biomarkers

  • Polybromo 1

  • Polycomb repressive complex 2

  • Cyclin Dependent Kinase Inhibitor 2A

  • Enhancer of zeste homolog 2

Drug/Treatment

  • Tazemetostat

  • GSK126

  • EZH2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved